Autoimmune uveitis silently destroys vision in millions of people worldwide, yet every approved therapy works by broadly suppressing the immune system — a blunt instrument that trades inflammation for infection risk, metabolic disruption, and long-term organ damage. A molecularly precise alternative would be transformative, and new research published in PNAS points toward one.
Costunolide (COS), a naturally occurring sesquiterpene lactone derived from plants such as Saussurea lappa and Inula helenium, was found to ameliorate experimental autoimmune uveitis by selectively targeting ubiquitin-specific protease 15 (USP15), a deubiquitinase enzyme. The mechanism centers on the TNF-α signaling cascade within retinal vascular endothelial cells: USP15 normally stabilizes pro-inflammatory mediators in this pathway, and COS inhibits that stabilization, thereby dampening the downstream inflammatory amplification that drives retinal tissue destruction. The researchers demonstrate target engagement, pathway specificity, and functional improvement in disease models, establishing a mechanistic chain from compound to clinical phenotype.
This finding sits at an interesting intersection of natural product pharmacology and precision immunology. Sesquiterpene lactones have long attracted attention for anti-inflammatory properties, but most prior work described broad NF-κB inhibition without a defined molecular target — leaving questions about selectivity and safety unanswered. Identifying USP15 as the functional anchor of COS activity substantially upgrades the compound's translational credibility. Deubiquitinases have emerged as a compelling but underexploited drug target class; their specificity for discrete regulatory nodes in inflammatory signaling could theoretically deliver pathway-selective immunomodulation rather than global suppression. That said, the current evidence appears primarily preclinical, and the gap between animal models of uveitis and human autoimmune disease is historically wide. Ocular pharmacokinetics — achieving therapeutic concentrations in posterior eye compartments without systemic exposure — remain a formidable barrier. This work is best characterized as a mechanistically rigorous early-stage finding that meaningfully advances the case for USP15 as a druggable target in ocular inflammation.